Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation

Targeted therapy has achieved great success in advanced non-small lung cancer (NSCLC) with driver genes, and neoadjuvant-targeted therapy is increasingly being investigated. Although neoadjuvant-targeted therapy with EGFR-TKI and ALK-TKI showed good efficacy, there is no report of neoadjuvant-target...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Chaoyuan Liu, Min Lu, Yang Yang, Xiang Wang, Fang Ma, Xianling Liu
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2022-08-01
סדרה:	Frontiers in Oncology
נושאים:	lung cancer BRAF V600E mutation neoadjuvant targeted therapy major pathologic response
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fonc.2022.961539/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!